Akebia Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
AKBA$0.54+1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity (Deficit)
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders'(Deficit) Equity | ||||||
|---|---|---|---|---|---|---|
| (dollars in thousands) · Shares · Amount | ||||||
| Balance at December 31, 2022 | 184,135,714 | $2 | $1,562,247 | $6 | $(1,557,025) | $5,230 |
| Issuance of common stock, net of issuance costs | 6,189,974 | — | 6,708 | — | — | 6,708 |
| Proceeds from sale of stock under employee stock purchase plan | 200,194 | — | 85 | — | — | 85 |
| Stock-based compensation expense | — | — | 9,317 | — | — | 9,317 |
| Restricted stock unit vesting | 4,054,407 | — | — | — | — | — |
| Exercise of options | 2,250 | — | 1 | — | — | 1 |
| Net loss | — | — | — | — | (51,925) | (51,925) |
| Balance at December 31, 2023 | 194,582,539 | $2 | $1,578,358 | $6 | $(1,608,950) | $(30,584) |
| Issuance of common stock, net of issuance costs | 27,532,942 | — | 42,495 | — | — | 42,495 |
| Proceeds from sale of stock under employee stock purchase plan | 189,732 | — | 153 | — | — | 153 |
| Stock-based compensation expense | — | — | 7,775 | — | — | 7,775 |
| Restricted stock unit vesting | 2,099,540 | — | — | — | — | — |
| Exercise of options | 444,239 | — | 386 | — | — | 386 |
| Net loss | — | — | — | — | (69,410) | (69,410) |
| Balance at December 31, 2024 | 224,848,992 | $2 | $1,629,167 | $6 | $(1,678,360) | $(49,185) |
| Warrants exercised, cashless | 1,408,588 | — | 7,494 | — | — | 7,494 |
| Issuance of common stock, net of issuance costs | 35,287,364 | — | 66,449 | — | — | 66,449 |
| Proceeds from sale of stock under employee stock purchase plan | 187,422 | — | 230 | — | — | 230 |
| Stock-based compensation expense | — | — | 11,283 | — | — | 11,283 |
| Restricted stock unit vesting | 2,486,599 | — | — | — | — | — |
| Exercise of options | 1,205,853 | — | 1,684 | — | — | 1,684 |
| Net loss | — | — | — | — | (5,345) | (5,345) |
| Balance at December 31, 2025 | 265,424,818 | $2 | $1,716,307 | $6 | $(1,683,705) | $32,610 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.